ANVS News and Press, Annovis Bio Inc. From 01/20/24

2024-01-20 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings r...

2024-01-20 01:54:32 ET Summary Annovis Bio has two upcoming major catalysts, a phase 2/3 AD clinical trial and a phase 3 PD clinical trial. The investigational drug, Buntanetap, is an enantiomer of a molecule previously tested for AD, with no success. We believe that the likel...

2024-01-19 15:00:29 ET More on the markets SPY Is At Its Highest Risk Level (Technical Analysis) Recession Forecasting: Indicators That Actually Help Your Portfolio (Part 3) New Secular Bull Markets Hidden In Plain Sight Investors retract capital from the fun...

2024-01-06 02:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-05 12:31:54 ET Gainers: Revelstone Capital Acquisition Corp ( RCAC ) +90% . Ainos ( AIMD ) +72% . Banzai International ( BNZI ) +62% . Safe and Green Development ( SGD ) +41% . Swvl Holdings ( SWVL ) +41% . Zoomcar Ho...

BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CE...

BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with ...

2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...

BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Wal...

2023-11-27 14:53:19 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Annovis Bio reports Q3 results Annovis Bio shares fall after pricing units offering at discount Seeking Alpha’s Quant Rating on Annovis Bio ...